- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
PACS software drives ISG's growth
ISG Technologies continues to move forward from its proxy fight of a year ago. The Mississauga, Ontario-based medical imaging software developer reported an 8% increase in revenue for its 1998 fiscal first quarter, bringing sales to a company record for
ISG Technologies continues to move forward from its proxy fight of a year ago. The Mississauga, Ontario-based medical imaging software developer reported an 8% increase in revenue for its 1998 fiscal first quarter, bringing sales to a company record for the period.
ISG reported revenues of $5.8 million (U.S.) for the period (end-September), compared with $5.4 million in the first quarter of 1997. Net income was $6400, compared with a net loss of $780,000 in the same period last year. No extraordinary charges were reported during the quarter. The company increased its backlog during the period by more than $6.3 million, representing multiyear agreements for licensed software and contract engineering work, according to the firm.
While revenues from the company's image-guided surgery line were down significantly, substantial gains in sales of ISG's Viewing and Reading Station (VRS) PACS software offset the loss, resulting in overall flat revenues of $2.8 million for the company's licensed software efforts. Contract R&D revenues rose 48% to $2.8 million.
The company also reported favorable developments in its IAP medical imaging console software business. In other quarterly developments, ISG released a Windows NT version of its VRS product line. Previously, VRS was based exclusively on the Unix operating system.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.
